Outset Medical's Q225 Earnings: Steady Growth & Cybersecurity Clearance

Outset Medicals Q2 2025 earnings report showcases steady growth with a 5% increase in full-year revenue to $119.5 million. The company expanded gross margins, cut cash burn, and narrowed losses. Console sales grew 11% in Q4, consumables rebounded, and recurring revenue made up 88.7% of the years total. Operations improved with less debt, better clinical outcomes, and high customer satisfaction. The next-gen Tablo received FDA clearance, and the pipeline is growing, setting the stage for stronger growth in 2026. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7dc482a386e94f7c